These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 26965867

  • 21. Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B.
    Tello-Aburto R, Hallada LP, Niroula D, Rogelj S.
    Org Biomol Chem; 2015 Oct 28; 13(40):10127-30. PubMed ID: 26400369
    [Abstract] [Full Text] [Related]

  • 22. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
    Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D, Takahashi Y, Akamatsu Y.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2343-5. PubMed ID: 19307118
    [Abstract] [Full Text] [Related]

  • 23. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
    Milo LJ, Lai JH, Wu W, Liu Y, Maw H, Li Y, Jin Z, Shu Y, Poplawski SE, Wu Y, Sanford DG, Sudmeier JL, Bachovchin WW.
    J Med Chem; 2011 Jul 14; 54(13):4365-77. PubMed ID: 21634429
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y, Liu X, Xue J, Liu L, Liang T, Li W, Yang X, Hou X, Fang H.
    J Med Chem; 2020 May 14; 63(9):4701-4715. PubMed ID: 32267687
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
    Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould AE, Hales P, Seager BA, Charron CL, Bruzzese F, Yang X, Zhao X, Huang SC, Hutton CA, Burrows JN, Winzeler EA, Avery VM, Dick LR, Tilley L.
    J Med Chem; 2018 Nov 21; 61(22):10053-10066. PubMed ID: 30373366
    [Abstract] [Full Text] [Related]

  • 28. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
    Yang Y, Wang K, Wu B, Yang Y, Lai F, Chen X, Xiao Z.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127508. PubMed ID: 32853683
    [Abstract] [Full Text] [Related]

  • 29. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM, Huang RZ, Yao GY, Liao ZX, Pan YM, Wang HS.
    Eur J Med Chem; 2017 Jan 27; 126():259-269. PubMed ID: 27889629
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
    Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S.
    J Med Chem; 2014 Mar 27; 57(6):2726-35. PubMed ID: 24524217
    [Abstract] [Full Text] [Related]

  • 32. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
    Hu G, Lin G, Wang M, Dick L, Xu RM, Nathan C, Li H.
    Mol Microbiol; 2006 Mar 27; 59(5):1417-28. PubMed ID: 16468986
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
    Cheemanapalli S, Anuradha CM, Madhusudhana P, Mahesh M, Raghavendra PB, Kumar CS.
    Anticancer Agents Med Chem; 2016 Mar 27; 16(11):1496-1510. PubMed ID: 27173965
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N, Ettari R, Lavecchia A, Di Giovanni C, Scarbaci K, Troiano V, Grasso S, Novellino E, Schirmeister T, Zappalà M.
    Eur J Med Chem; 2013 Jun 27; 64():23-34. PubMed ID: 23639651
    [Abstract] [Full Text] [Related]

  • 39. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N, Sarraf D, Maréchal X, Janmamode N, Le Guével R, Genin E, Reboud-Ravaux M, Vidal J.
    Eur J Med Chem; 2018 Feb 10; 145():570-587. PubMed ID: 29339252
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.